Health Care Down After Pfizer, Novo Nordisk Earnings -- Health Care Roundup

Health-care companies fell after weak earnings.

Pfizer declined as weakened COVID-19 drug demand weighed on quarterly sales.

Shares of Danish obesity-drug maker Novo Nordisk plunged after it warned that it expects lower prices for Ozempic and Wegovy in the U.S. to weigh on 2026 sales, dragging them 5%-to-13% lower than 2025 levels around 309.06 billion Danish kroner, or about $48.79 billion.

Merck shares rose after the Big Pharma company cited strong demand for oncology, respiratory, and cardiometabolic drugs for its brisk quarterly sales growth.

Write to Rob Curran at [e-mail]

(END) Dow Jones Newswires

02-03-26 1747ET